BACKGROUND AND OBJECTIVES: Secondary hyperparathyroidism (SHPT) can lead to significant morbidity, mortality, and additional healthcare resource utilization in chronic kidney disease (CKD) stage 5. The objective of this study was to examine healthcare costs and utilization, and the risks of dialysis or mortality, among pre-dialysis CKD patients with and without SHPT. RESEARCH DESIGN AND METHODS: This retrospective cohort study examined insurance claims from 66 644 adult, pre-dialysis, CKD patients with and without SHPT during a 72-month period. Annualized estimates of healthcare costs and utilization, and disease progression to dialysis or death following index CKD diagnosis were compared. RESULTS: Post-index annualized costs and inpatient healthcare resource utilization was higher in those with SHPT in both unadjusted and adjusted (controlling for gender, age, plan type, payer type, geographic region, physician specialty, pre-index co-morbidities, and pre-index total healthcare costs), and unmatched and matched analyses. Kaplan-Meier analysis demonstrated that the rate of progression to dialysis or death was higher for CKD with SHPT compared to CKD without SHPT, and Cox proportional hazard models suggested that CKD patients with SHPT were more than four to five times as likely to initiate dialysis or die as compared to CKD without SHPT. CONCLUSION: SHPT in pre-dialysis CKD patients is associated with significantly greater healthcare costs, inpatient hospitalizations, and a faster rate of disease progression compared to pre-dialysis CKD without SHPT. Since observational studies are designed to demonstrate associations rather than causality, further investigation is required to confirm these findings.
BACKGROUND AND OBJECTIVES: Secondary hyperparathyroidism (SHPT) can lead to significant morbidity, mortality, and additional healthcare resource utilization in chronic kidney disease (CKD) stage 5. The objective of this study was to examine healthcare costs and utilization, and the risks of dialysis or mortality, among pre-dialysis CKDpatients with and without SHPT. RESEARCH DESIGN AND METHODS: This retrospective cohort study examined insurance claims from 66 644 adult, pre-dialysis, CKDpatients with and without SHPT during a 72-month period. Annualized estimates of healthcare costs and utilization, and disease progression to dialysis or death following index CKD diagnosis were compared. RESULTS: Post-index annualized costs and inpatient healthcare resource utilization was higher in those with SHPT in both unadjusted and adjusted (controlling for gender, age, plan type, payer type, geographic region, physician specialty, pre-index co-morbidities, and pre-index total healthcare costs), and unmatched and matched analyses. Kaplan-Meier analysis demonstrated that the rate of progression to dialysis or death was higher for CKD with SHPT compared to CKD without SHPT, and Cox proportional hazard models suggested that CKDpatients with SHPT were more than four to five times as likely to initiate dialysis or die as compared to CKD without SHPT. CONCLUSION: SHPT in pre-dialysis CKDpatients is associated with significantly greater healthcare costs, inpatient hospitalizations, and a faster rate of disease progression compared to pre-dialysis CKD without SHPT. Since observational studies are designed to demonstrate associations rather than causality, further investigation is required to confirm these findings.
Authors: Guillaume Jean; Marie Hélène Lafage-Proust; Jean Claude Souberbielle; Sylvain Lechevallier; Patrik Deleaval; Christie Lorriaux; Jean Marc Hurot; Brice Mayor; Manolie Mehdi; Charles Chazot Journal: PLoS One Date: 2018-06-18 Impact factor: 3.240
Authors: Charles W Bishop; Stephen A Strugnell; Philipp Csomor; Edelgard Kaiser; Akhtar Ashfaq Journal: Am J Nephrol Date: 2022-05-12 Impact factor: 4.605
Authors: Giuseppe Turchetti; S Bellelli; M Amato; S Bianchi; P Conti; A Cupisti; V Panichi; A Rosati; F Pizzarelli Journal: Eur J Health Econ Date: 2016-10-03